The a-catulin/dystrophin-associated protein complex regulates GPCR function
α-catulin/肌营养不良蛋白相关蛋白复合物调节 GPCR 功能
基本信息
- 批准号:8270236
- 负责人:
- 金额:$ 29.35万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2012
- 资助国家:美国
- 起止时间:2012-06-07 至 2017-03-31
- 项目状态:已结题
- 来源:
- 关键词:Adrenergic AgentsAdrenergic ReceptorAffectAfghanistanAmino AcidsArterial Fatty StreakBenignBenign Prostatic HypertrophyBindingBiological AssayBlood VesselsCardiovascular DiseasesCell Culture TechniquesCellsCollaborationsComplexCouplesCouplingDataDistalDrug Delivery SystemsDrug usageDystrophinDystrophin-Associated Protein ComplexElderlyEpinephrineFamilyG Protein-Coupled Receptor SignalingG-Protein-Coupled ReceptorsGenetic ScreeningGlutamate ReceptorGoalsHistamine ReceptorHormonesHumanHybridsHypertensionHypertrophyImmunoprecipitationIon ChannelIraqMalignant HypertensionMapsMass Spectrum AnalysisMembrane ProteinsMigraineModelingMolecularNorepinephrinePathway interactionsPharmaceutical PreparationsPhospholipase CPhosphotransferasesPost-Traumatic Stress DisordersProteinsProteomicsReceptor ActivationRecruitment ActivityReportingRoleSafetySequence AnalysisSerum Response FactorShapesSignal PathwaySignal TransductionSignaling MoleculeSignaling ProteinSomatostatin ReceptorStable Isotope LabelingStrokeTechniquesTestingUtrophinVeteransVinculinYeastsadrenergicbasecell motilitychemokine receptorcohortcombatdystrobrevinfightinghypertension treatmentin vivomalememberneuron lossnovelpreventprotein functionreceptorreceptor functionrestenosisrhoscaffoldsyntrophintherapeutic targetvascular smooth muscle cell migration
项目摘要
DESCRIPTION (provided by applicant): ?1-adrenergic receptors (ARs) are G-protein coupled receptors (GPCRs) that respond to sympathetic hormones norepinephrine and epinephrine, and are therapeutic targets for the treatment of hypertension, benign prostrate hypertrophy (BPH), and post-traumatic stress disorder (PTSD). ?1-ARs comprise 3 unique subtypes, ?1A, ?1B, and ?1D, which are ubiquitously expressed on blood vessels throughout the CNS. Although each subtype responds to norepinephrine/epinephrine and activates G?q/11 signaling, the ?1D-AR subtype performs a specialized role using mechanisms distinct from the ?1A-AR and ?1B-AR subtypes. For example, ?1D-ARs stimulate vascular smooth muscle cell migration, while the ?1A and ?1B-AR subtypes stimulate vascular smooth cell hypertrophy. The molecular mechanisms that permit ?1D-ARs to selectively activate pathways distinct from those used by the ?1A and ?1B-AR subtypes remains a major mystery in the field. Revealing the molecular mechanisms ?1D- ARs use to stimulate vascular smooth cell migration will identify new drug targets to treat CNS blood vessel restenosis and atherosclerotic plaque formation, prevent migraine associated with malignant hypertension and reduce the potential for stroke and neuronal cell death.
PUBLIC HEALTH RELEVANCE: This proposal will reveal how drugs affecting the adrenergic pathway (or "fight or flight") in the body cause blood vessels to change in shape and function. This has important implications for adrenergic drugs currently used to treat high blood pressure, benign prostatic hypertrophy (BPH) in elderly males and post-traumatic stress disorder (PTSD) in combat veterans returning from Iraq and Afghanistan. This information will provide crucial information about the long-term safety of using these drugs in BPH, PTSD and cardiovascular disease.
描述(由申请人提供):?1-肾上腺素能受体(AR)是响应交感激素去甲肾上腺素和肾上腺素的G蛋白偶联受体(GPCR),并且是用于治疗高血压、良性前列腺肥大(BPH)和创伤后应激障碍(PTSD)的治疗靶标。? 1-AR包括3种独特的亚型,?1A,?1B、?1D,其在整个CNS的血管上普遍表达。虽然每个亚型响应去甲肾上腺素/肾上腺素和激活G?Q/11信令,?1D-AR亚型使用不同于?1A和?1B-AR亚型。例如,?1D-ARs刺激血管平滑肌细胞迁移,而?1A和?1B-AR亚型刺激血管平滑肌细胞肥大。分子机制允许?1D-ARs选择性地激活不同于那些使用的途径?1A和?1B-AR亚型仍然是该领域的一个主要谜团。揭示分子机制?1 D-AR用于刺激血管平滑肌细胞迁移将确定新的药物靶点,以治疗CNS血管再狭窄和动脉粥样硬化斑块形成,预防与恶性高血压相关的偏头痛,并降低中风和神经元细胞死亡的可能性。
公共卫生关系:这项提议将揭示影响体内肾上腺素能通路(或“战斗或逃跑”)的药物如何引起血管形状和功能的变化。这对目前用于治疗高血压、老年男性良性前列腺肥大(BPH)和从伊拉克和阿富汗返回的退伍军人创伤后应激障碍(PTSD)的肾上腺素能药物具有重要意义。这些信息将提供有关在BPH,PTSD和心血管疾病中使用这些药物的长期安全性的关键信息。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Chris S Hague其他文献
Chris S Hague的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Chris S Hague', 18)}}的其他基金
The a-catulin/dystrophin-associated protein complex regulates GPCR function
α-catulin/肌营养不良蛋白相关蛋白复合物调节 GPCR 功能
- 批准号:
9035401 - 财政年份:2012
- 资助金额:
$ 29.35万 - 项目类别:
The a-catulin/dystrophin-associated protein complex regulates GPCR function
α-catulin/肌营养不良蛋白相关蛋白复合物调节 GPCR 功能
- 批准号:
8827808 - 财政年份:2012
- 资助金额:
$ 29.35万 - 项目类别:
The a-catulin/dystrophin-associated protein complex regulates GPCR function
α-catulin/肌营养不良蛋白相关蛋白复合物调节 GPCR 功能
- 批准号:
8640197 - 财政年份:2012
- 资助金额:
$ 29.35万 - 项目类别:
The a-catulin/dystrophin-associated protein complex regulates GPCR function
α-catulin/肌营养不良蛋白相关蛋白复合物调节 GPCR 功能
- 批准号:
8484849 - 财政年份:2012
- 资助金额:
$ 29.35万 - 项目类别:
The a-catulin/dystrophin-associated protein complex regulates GPCR function.
α-catulin/肌营养不良蛋白相关蛋白复合物调节 GPCR 功能。
- 批准号:
9380078 - 财政年份:2012
- 资助金额:
$ 29.35万 - 项目类别:
The a-catulin/dystrophin-associated protein complex regulates GPCR function.
α-catulin/肌营养不良蛋白相关蛋白复合物调节 GPCR 功能。
- 批准号:
9896833 - 财政年份:2012
- 资助金额:
$ 29.35万 - 项目类别:
相似海外基金
Structural basis for regulation of beta2 adrenergic receptor signaling by the dynamic post-translational modification S-palmitoylation
动态翻译后修饰S-棕榈酰化调节β2肾上腺素受体信号传导的结构基础
- 批准号:
10603466 - 财政年份:2023
- 资助金额:
$ 29.35万 - 项目类别:
Modulation of T lymphocyte Activation by Ã2-Adrenergic Receptor Signalling Pathways
α2-肾上腺素能受体信号通路对 T 淋巴细胞激活的调节
- 批准号:
RGPIN-2019-06980 - 财政年份:2022
- 资助金额:
$ 29.35万 - 项目类别:
Discovery Grants Program - Individual
Glucocorticoid and Adrenergic Receptor Signaling at the Neuroimmune Interface
神经免疫界面的糖皮质激素和肾上腺素能受体信号传导
- 批准号:
RGPIN-2019-04706 - 财政年份:2022
- 资助金额:
$ 29.35万 - 项目类别:
Discovery Grants Program - Individual
Modulation of T lymphocyte Activation by ß2-adrenergic Receptor Signalling Pathways
α2-肾上腺素能受体信号通路对 T 淋巴细胞激活的调节
- 批准号:
574979-2022 - 财政年份:2022
- 资助金额:
$ 29.35万 - 项目类别:
University Undergraduate Student Research Awards
Angiotensin-(1-7) and beta adrenergic receptor signaling in aging
衰老过程中血管紧张素 (1-7) 和 β 肾上腺素受体信号传导
- 批准号:
10629280 - 财政年份:2022
- 资助金额:
$ 29.35万 - 项目类别:
Angiotensin-(1-7) and beta adrenergic receptor signaling in aging
衰老过程中血管紧张素 (1-7) 和 β 肾上腺素受体信号传导
- 批准号:
10448574 - 财政年份:2022
- 资助金额:
$ 29.35万 - 项目类别:
Novel regulation of beta-adrenergic receptor function by phosphoinositide 3-kinase
磷酸肌醇 3-激酶对 β-肾上腺素能受体功能的新调节
- 批准号:
10591688 - 财政年份:2022
- 资助金额:
$ 29.35万 - 项目类别:
Modulation of T lymphocyte Activation by Ã2-adrenergic Receptor Signalling Pathways
α2-肾上腺素能受体信号通路对 T 淋巴细胞激活的调节
- 批准号:
574984-2022 - 财政年份:2022
- 资助金额:
$ 29.35万 - 项目类别:
University Undergraduate Student Research Awards
Modulation of T lymphocyte Activation by ß2-adrenergic Receptor Signalling Pathways
α2-肾上腺素能受体信号通路对 T 淋巴细胞激活的调节
- 批准号:
574985-2022 - 财政年份:2022
- 资助金额:
$ 29.35万 - 项目类别:
University Undergraduate Student Research Awards
The molecular mechanism of the crosstalk between the beta-2 adrenergic receptor and chemokine receptors in lymphocytes
淋巴细胞β2肾上腺素受体与趋化因子受体串扰的分子机制
- 批准号:
22K07118 - 财政年份:2022
- 资助金额:
$ 29.35万 - 项目类别:
Grant-in-Aid for Scientific Research (C)